A laboratory breakthrough uses small doses of caffeine to activate and deactivate gene-editing systems with precision, researchers report.
By yourNEWS Media Newsroom
Scientists have developed an experimental system that uses caffeine to control advanced gene-editing activity inside engineered cells, a finding that could influence future approaches to treating diseases such as cancer.
The research, conducted by a team at Texas A&M University, introduces a mechanism in which caffeine acts as a biological trigger for activating CRISPR-based tools. The work remains in early laboratory stages and has not been tested as a treatment in patients.
The system relies on synthetic proteins referred to as “caffebodies,” which are designed to respond specifically to caffeine. When exposed to a small dose—approximately 20 milligrams, or about one-fifth of a standard cup of coffee—the proteins initiate gene-editing activity. As caffeine is metabolized and cleared by the body, the activity naturally subsides.
Researchers say this approach allows for targeted activation within pre-engineered cells, reducing the likelihood of unintended effects elsewhere. The method falls under chemogenetics, a field focused on controlling biological processes through chemical signals.
To complement the activation mechanism, the system also incorporates a secondary control using the drug rapamycin. This compound can be administered to rapidly halt the gene-editing process, providing an additional layer of regulation beyond the natural decline of caffeine levels.
The dual-switch design is intended to offer more flexibility in managing treatments that rely on continuous cellular activity. Researchers noted that the ability to turn gene-editing functions on and off could be particularly relevant for therapies requiring careful dose control.
One potential application involves CAR-T cell therapy, a form of immunotherapy that modifies a patient’s immune cells to target cancer. These treatments can be effective but may trigger severe immune responses due to sustained activation. A caffeine-controlled system could allow clinicians to regulate when these cells are active.
The researchers also suggested the platform could be adapted for other conditions, including metabolic disorders, by linking gene activity to externally controlled signals. However, such uses remain theoretical at this stage.
The study’s authors emphasized that the findings represent proof-of-concept work conducted under controlled laboratory conditions. Additional research, including preclinical and clinical testing, would be required before any medical application could be considered.
The development reflects ongoing efforts to improve precision in gene-based therapies by introducing mechanisms that allow for adjustable and reversible control of cellular functions.
Source: Natural News